Overview Financials News + Filings Key Docs Charts Transactions Holdings Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Acq. announced
Inv. presentation
Auditor change
Credit agrmnt [a]
|
|
SPECTRUM PHARMACEUTICALS INC (SPPI)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 07/27/2023 |
8-K
| Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits Interac... |
| 05/17/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Spectrum Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement Boston, MA, May 17, 2023 - Spectrum Pharmaceuticals, Inc. , a biopharmaceutical Company focused on novel and targeted oncology announced today that on May 16, 2023, the Company received a written notification from the Listing Qualifications Staff of the Nasdaq Stock Market LLC that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550. The Company previously received notification from the Staff on November 1, 2022, that its common stock failed to maintain a minimum bid price of $1.00 or more over the previous 30 consecutive business days, as required by the Nasdaq Listing Rules. Since then, the Staff has determined that for the 10 consecutive busi..." |
|
| 05/09/2023 |
8-K
| Quarterly results |
| 05/01/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 04/25/2023 |
8-K
| Quarterly results |
| 04/04/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits ... |
| 04/03/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/22/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 03/10/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 02/09/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Spectrum Pharmaceuticals Receives Permanent J-Code for ROLVEDON ™ Injection from U.S. Centers for Medicare & Medicaid Services Boston, MA, February 8, 2023 - Spectrum Pharmaceuticals, Inc. , a biopharmaceutical company focused on novel and targeted oncology announced today that a permanent J-code, J1449, has been issued for ROLVEDON Injection by the U.S. Centers for Medicare & Medicaid Services effective as of April 1, 2023. “This is an important milestone in the ROLVEDON launch. A permanent J-code will enable a more efficient and predictable reimbursement in the outpatient setting. The combination of a permanent J-code on April 1, 2023 and ROLVEDON'S inclusion in the National Comprehensive Cancer Network ® Supportive Care Guidelines announced on December 6, 2022 are key elements in establ..." |
|
| 01/31/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 01/04/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Confidential Separation Agreement and General Release, between Spectrum Pharmaceuticals, Inc. and Francois Lebel",
"Consulting Agreement, between Spectrum Pharmaceuticals, Inc. and Francois Lebel",
"Spectrum Pharmaceuticals Announces Management Changes Boston, MA, January 4, 2023 - Spectrum Pharmaceuticals, Inc. , a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that Francois J. Lebel, M.D., Executive Vice President and Chief Medical Officer, will step down from his role to pursue other opportunities, effective immediately. The company's clinical development function will be led by Dr. Shanta Chawla, Vice President, Clinical Development, also effective immediately. Dr. Chawla was the principal physician on the ROLVEDON ™ injection Phase 3 program and was instrumental in successfully navigating the BLA submission that resulted in the drug's approval. Dr. Lebel will serve as a consultant to Spectrum through March 2023 to facilitate a seamless..." |
|
| 11/10/2022 |
8-K
| Quarterly results |
| 11/07/2022 |
8-K
| Quarterly results |
| 10/24/2022 |
8-K
| Quarterly results |
| 09/23/2022 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549",
"Form of Warrant",
"Loan and Security Agreement, by and among Spectrum Pharmaceuticals, Inc., the other borrowers party thereto, the lenders party thereto and SLR Investment Corp., as collateral agent",
"Spectrum Pharmaceuticals Announces Debt Financing Agreement with SLR Capital Partners with $30 Million Funded at Closing",
"Spectrum Pharmaceuticals Provides Update on Poziotinib Following FDA Oncologic Drugs Advisory Committee Meeting" |
|
| 09/12/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 08/11/2022 |
8-K
| Quarterly results |
| 08/03/2022 |
8-K
| Other Events Interactive Data |
| 06/23/2022 |
8-K
| Quarterly results |
| 06/10/2022 |
8-K
| Quarterly results |
| 05/17/2022 |
8-K
| Quarterly results |
| 05/12/2022 |
8-K
| Quarterly results |
| 05/05/2022 |
8-K
| Quarterly results |
| 03/17/2022 |
8-K
| Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits Interactive Data |
| 03/11/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 03/10/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 02/23/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 01/06/2022 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549",
"Securities Purchase Agreement, between Spectrum Pharmaceuticals, Inc. and Hanmi Pharmaceutical Co., Ltd",
"Spectrum Pharmaceuticals Announces New Strategic Investment by Hanmi Pharmaceutical January 4, 2022 HENDERSON, Nev.——Jan. 4, 2022— Spectrum Pharmaceuticals , a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a $20 million equity investment by Hanmi Pharmaceutical along with revisions to the licensing agreements for ROLONTIS ® and poziotinib. Under the terms of the strategic investment, Hanmi entered into a $20 million equity purchase agreement that will be priced at $1.60 per share. “This investment represents a strengthening in the relationship that we have with Hanmi,” said Tom Riga, President and CEO of Spectrum Pharmaceuticals. “We look forward to our continued partnership with Hanmi and to achieving the shared goal of gaining FDA approval fo..." |
|
| 12/03/2021 |
8-K
| Quarterly results |
| 11/10/2021 |
8-K
| Quarterly results |
| 08/12/2021 |
8-K
| Quarterly results |
| 06/22/2021 |
8-K
| Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits Interactive Data |
| 06/03/2021 |
8-K
| Quarterly results |
|
|
|